 This study, AEZS-130-P01 Study P01, was the first of two studies as agreed with the European Medicines Agency EMA in the Companys Pediatric Investigation Plan PIP for macimorelin. The goal of Study P01 was to establish a dose that could both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD. 